Copyright
©The Author(s) 2018.
World J Gastroenterol. Oct 21, 2018; 24(39): 4428-4435
Published online Oct 21, 2018. doi: 10.3748/wjg.v24.i39.4428
Published online Oct 21, 2018. doi: 10.3748/wjg.v24.i39.4428
Therapy | Agent | Clinical status | Ref. |
Five peptides combination with oxaliplatin-based chemotherapy | Oxaliplatin | Phase II | [34] |
Panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) vs FOLFOX4 alone | Fluorouracil, Oxaliplatin | Phase III trial | [35] |
Checkpoint inhibitors | Nivolumab and pembrolizumab | Phase 2 study | [36] |
Combination vaccine treatment of five therapeutic epitope-peptides | Fluorouracil, irinotecan or oxaliplatin | Phase I | [37] |
Autologous dendritic cell based adoptive immunotherapy | - | Phase I-II | [38] |
Autologous antigen-activated dendritic cells in the treatment of CRC | - | Phase I-II | [39] |
Adjuvant chemotherapy (FOLFOX) | 5-fluorouracil (FU)/leucovorin (LV) | Phase III | [40] |
- Citation: Tiwari A, Saraf S, Verma A, Panda PK, Jain SK. Novel targeting approaches and signaling pathways of colorectal cancer: An insight. World J Gastroenterol 2018; 24(39): 4428-4435
- URL: https://www.wjgnet.com/1007-9327/full/v24/i39/4428.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i39.4428